Summary of project PR000866
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000866. The data can be accessed directly via it's Project DOI: 10.21228/M8R963 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR000866 |
| Project DOI: | doi: 10.21228/M8R963 |
| Project Title: | Transgenic Parkinson's Mice Following Immunotherapy |
| Project Summary: | An UHPLC-HRMS Metabolomics and Lipidomics Study of Stool from Transgenic Parkinson's disease Mice Following Immunotherapy. Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the brain as well as degeneration of motor and non-motor circuitry. The cause of neuronal death is currently unknown, although chronic neuroinflammation, aggregated α-synuclein, mitochondrial dysfunction and oxidative stress have all been implicated. Gliosis has been shown to exacerbate neuroinflammation via secretion of pro-inflammatory cytokines, and there is a subsequent infiltration of T lymphocytes (T-cells), into the brain of PD patients. Using liquid chromatography-high resolution mass spectrometry (LC-HRMS), we have observed metabolomic changes in stool samples, thought to be associated with the potential disease-modifying effect of an immunotherapy administered to transgenic Parkinsonian (A53T) mice. Significant elevations (p<0.05) in metabolites associated with immune response (taurine, histamine and its methylated product, 3-methylhistamine) are identified as being higher in the mice undergoing immunotherapy. Furthermore, a reduction in triacylglycerols (TG) and diacylglyceols (DG) expression in stool following immunotherapy suggests a regulation of lipid breakdown or biosynthesis with the vaccine. These “omics” markers (among others reported in this article) along with weight gain and increased life expectancy suggest that the immunotherapy is positively modifying the disease state. |
| Institute: | University of Florida |
| Department: | CHEMISTRY |
| Last Name: | Gill |
| First Name: | Emily |
| Address: | BUCKMAN DRIVE, GAINESVILLE, FL, 32611, USA |
| Email: | emilygill2014@ufl.edu |
| Phone: | (352) 222-9749 |
| Funding Source: | Southeast Center for Intergrated Metabolomics |
| Publications: | J Proteome Res, 2019. |
| Contributors: | Emily L. Gill, Jeremy P. Koelmel, Laurel Meke, Richard A. Yost, Timothy J. Garrett, Michael S. Okun, Catherine Flores, and Vinata Vedam-Mai |
Summary of all studies in project PR000866
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST001281 | Transgenic Parkinson's Mice Following Immunotherapy | Mus musculus | University of Florida | MS* | 2020-01-13 | 1 | 7 | Uploaded data (6.6G)* |
